Basilea Pharmaceutica

Grenzacherstrasse 487
Basel
CH-4005

Tel: 41-61-6061-111
Fax: 41-61-6061-112

About Basilea Pharmaceutica

Basilea Pharmaceutica is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.
YEAR FOUNDED:
October 17, 2000
LEADERSHIP:
Founder: Jan G. J. van de Winkel, Ph.D.
CEO: Ronald Scott
CMO (Medical): Achim Kaufhold
CTO: Günter Ditzinger
CFO: Donato Spota
CSO (Scientific): Laurenz Kellenberger
JOBS:
Please click here for.
CLINICAL TRIAL
Please click here for clinical trial information.

PRODUCTS:
All Products

270 articles about Basilea Pharmaceutica

Basilea Pharmaceutica's Toctino(R) (Alitretinoin) Included In New Dermatology Treatment Guidelines In Germany

3/26/2009
Basilea Pharmaceutica's Toctino(R) Receives Marketing Authorization In Austria

3/17/2009
Basilea Pharmaceutica's Toctino(R) Receives Marketing Authorization in Belgium and Luxemburg

3/11/2009
Basilea Pharmaceuticas Toctino(R) Accepted for Use by the Scottish Medicines Consortium

3/9/2009
Basilea Pharmaceutica Presents Research Data On A Novel Antibiotic At The Anti-Infectives Partnering & Deal-Making Summit

3/6/2009
Basilea Pharmaceutica Confirms Its Press Release of February 24, 2009

2/26/2009
Basilea Pharmaceutica Reports 2008 Financial Results

2/24/2009
Basilea Pharmaceutica Files Against Johnson & Johnson Over 'Superbug' Antibiotic

2/24/2009
Basilea Pharmaceutica Announces Zevtera(TM) Review Process Delayed in EU

2/24/2009
Basilea Pharmaceutica Implements Previously Announced Program Focusing On Key Value Drivers

2/11/2009
Basilea Pharmaceutica to Add 100 New Jobs; Company to Focus on Commercialization of Its Products and High Priority Programs

1/27/2009
Basilea Pharmaceutica Opens U.S. Phase III Study On Alitretinoin For The Treatment Of Severe Chronic Hand Eczema

12/17/2008
FDA Delays Johnson & Johnson (JOBS), Basilea Pharmaceutica Antibiotic Approval

11/26/2008
Basilea Pharmaceutica Release: Zevtera(TM) (Ceftobiprole Medocaril), The Novel Anti-MRSA Broad-Spectrum Antibiotic, Receives A Positive Opinion From The CHMP

11/21/2008
Basilea Pharmaceutica Release: Ceftobiprole, a New Anti-MRSA Broad-Spectrum Antibiotic, Receives Approval by Swissmedic

11/13/2008
Basilea Pharmaceutica Presents Research Data at ICAAC/IDSA on Novel Antibiotic Addressing the Emerging Threat from Multi-resistant Gram-negative Bacteria

10/27/2008
Basilea Pharmaceutica's Toctino(R) (alitretinoin) Receives Marketing Authorization in France

10/21/2008
Basilea Pharmaceutica Announces New Data to be Presented on Ceftobiprole and Isavuconazole at ICAAC/Infectious Diseases Society of America

10/20/2008
Basilea Pharmaceutica's Toctino(R) (alitretinoin) Receives Marketing Authorization in Finland

10/15/2008
Basilea Pharmaceutica's Toctino(R) (alitretinoin) Receives Marketing Authorization in Germany

10/6/2008

First
Previous
11
12
13
14
Next
Last